Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Mem. Inst. Oswaldo Cruz ; 99(8): 877-882, dez. 2004. ilus, graf
Artículo en Inglés | LILACS | ID: lil-393772

RESUMEN

In the context of universal access to antiretroviral therapy, the surveillance of human immunodeficiency virus type 1 (HIV-1) genetic diversity and resistance becomes pivotal. In this work our purpose was to describe the genetic variability; prevalence of drug-resistance mutations; and genotypic resistance profiles in HIV-1 infected individuals under antiretroviral treatment, from the Federal District, Brasília, Central Brazil. The entire viral protease and codons 19 to 234 of the reverse transcriptase gene from 45 HIV-1 isolates were amplified and sequenced for subtyping and genotyping. By phylogenetic analysis, 96 percent of the samples clustered with subtype B and the remaining 4 percent with HIV-1 subtype F sequences. One major protease inhibitor resistance-associated mutation, I50V, was detected in 38 percent of the samples. Minor mutations were also found at the protease gene: L10I/V (7 percent), K20M (2 percent), M36I (11 percent), L63P (20 percent), A71T (2 percent), and V77I (7 percent). Many mutations associated with reduced susceptibility to nucleoside or non-nucleoside reverse transcriptase inhibitors were detected: M41L (11 percent), E44D (4 percent), D67N (11 percent), T69D (2 percent), K70R (11 percent), L74V (2 percent), L100I (4 percent), K103N (18 percent), V118I (9 percent), Y181C (11 percent), M184V (18 percent), G190A (4 percent), T215Y (4 percent), and K219E (4 percent). This study has shown that 84 percent of the studied population from the Federal District, showing evidences of therapy failure, presented viral genomic mutations associated with drug resistance. The main antiretrovirals to which this population showed resistance were the PI amprenavir (38 percent), the NNRTIs delavirdine, nevirapine (31 percent), and efavirenz (24 percent), and the NRTIs lamivudine (18 percent), abacavir, and zidovudine (13 percent).


Asunto(s)
Humanos , Fármacos Anti-VIH , Farmacorresistencia Viral , Infecciones por VIH , VIH-1 , Terapia Antirretroviral Altamente Activa , Brasil , Variación Genética , Genotipo , Transcriptasa Inversa del VIH , Mutación , Reacción en Cadena de la Polimerasa , ARN Viral , Carga Viral
2.
Mem. Inst. Oswaldo Cruz ; 84(2): 241-3, abr.-jun. 1989.
Artículo en Portugués | LILACS | ID: lil-79143

RESUMEN

Descrevemos o isolamento de Corynebacterium diphtheriae toxígeno de espermocultura. O microrganismo foi identificado pelo teste de fluorescência sob luz ultravioleta, pesquisa da enzima pirazina-carboxilamidase (Pyz), testes de virulência in vitro e in vivo (imunodifusäo radial simples, cultura de células e teste intradérmico em cobaio). A amostra foi inicialmente considerada atoxígena pelo teste de imunodifusäo radial simples, mas sua virulência foi observada posteriormente quando os testes acima foram aplicados. Sem adecuada especificaçäo, a amostra poderia ter sido considerada como um "difteróide"


Asunto(s)
Corynebacterium diphtheriae/aislamiento & purificación , Difteria/diagnóstico , Semen/patogenicidad , Corynebacterium diphtheriae/patogenicidad , Medios de Cultivo , Virulencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA